

Resource Summary Report

Generated by [NIF](#) on Sep 9, 2026

NCI-H3255

RRID:CVCL_6831

Type: Cell Line

Proper Citation

RRID:CVCL_6831

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_6831

Proper Citation: RRID:CVCL_6831

Description: Cell line NCI-H3255 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Lung adenocarcinoma

Defining Citation: [PMID:11030152](#), [PMID:12759538](#), [PMID:16187286](#), [PMID:20215515](#), [PMID:20679594](#), [PMID:22961666](#), [PMID:26202522](#), [PMID:26361996](#), [PMID:26554430](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H3255

Synonyms: H3255, H-3255, H3255_DA, NCIH3255

Cross References: BTO:BTO_0006539, EFO:EFO_0003123, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2882, BioSample:SAMN03471808, BioSample:SAMN10988059, cancercellines:CVCL_6831, Cell_Model_Passport:SIDM00046, ChEMBL-Cells:ChEMBL4295484, ChEMBL-Targets:ChEMBL4296476, Cosmic:897734, Cosmic:903623, Cosmic:914952, Cosmic:1028937, Cosmic:1128245, Cosmic:1146914, Cosmic:2647633, Cosmic-

CLP:1247873, DepMap:ACH-000109, DepMap:ACH-002137, EGA:EGAS00001000978, GDSC:1247873, GEO:GSM63349, GEO:GSM108847, GEO:GSM108848, GEO:GSM253411, GEO:GSM434297, GEO:GSM794371, GEO:GSM817108, GEO:GSM827356, GEO:GSM1374743, GEO:GSM1669833, IARC_TP53:28350, IGRhCellID:H3255_DAGEO, LiGeA:CCLE_545, NCI-DTP:NCI-H3255, PharmacDB:NCIH3255_1108_2019, PRIDE:PXD001548, PRIDE:PXD002224, PRIDE:PXD002556, PRIDE:PXD030304, Progenetix:CVCL_6831, PubChem_Cell_line:CVCL_6831, Wikidata:Q54908036

ID: CVCL_6831

Record Creation Time: 20220427T220839+0000

Record Last Update: 20260905T181245+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H3255.

Warning: Discontinued: ATCC; CRL-2882

Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Pulice JL, et al. (2025) Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma. *Molecular cell*, 85(7), 1311.

Civita S, et al. (2025) Nanoscale engagement of programmed death ligand 1 (PD-L1) in membrane lipid raft domains of cancer cells. *The FEBS journal*.

Baro M, et al. (2025) Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation. *Cell chemical biology*, 32(6), 839.

Sadeghi M, et al. (2024) Biased signaling by mutant EGFR underlies dependence on PKC?? in lung adenocarcinoma. *Cell reports*, 43(12), 115026.

Sun F, et al. (2024) Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2. *eLife*, 12.

Marrocco I, et al. (2023) L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab. *Cell reports. Medicine*, 4(8), 101142.

Cheung AH, et al. (2023) MLK4 promotes glucose metabolism in lung adenocarcinoma through CREB-mediated activation of phosphoenolpyruvate carboxykinase and is regulated by KLF5. *Oncogenesis*, 12(1), 35.

Theard PL, et al. (2020) Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer. *eLife*, 9.